Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338649 | 1.00 | ACE (0.62) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL478774 | 1.00 | ACE (0.62) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2310637 | 0.92 | CTSS (0.60) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2715763 | 0.92 | CTSS (0.60) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2310645 | 0.92 | CTSS (0.60) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL3824787 | 0.91 | ACE (0.54) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL31407761 | 0.90 | ITGB3 (0.61) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL7436985 | 0.89 | CTSS (0.53) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL6749429 | 0.89 | CTSS (0.52) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL13538229 | 0.88 | KLK5 (0.57) | ACEITGB3ITGA2BCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024224086-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024224093-A1 | DESMURAMYLPEPTIDE DIEESTERS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| EP-4444711-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-10-16 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-1102789-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2001-05-30 | — | — | EP | disclosed |
| US-6180611-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2001-01-30 | — | — | US | disclosed |
| US-6114310-A | THERAPY FOR MICROBIAL INFECTIONS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0509354-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 2000-08-23 | — | — | EP | disclosed |
| EP-1020467-A1 | N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF | UBE INDUSTRIES LIMITED (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000008046-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2000-02-17 | — | — | WO | disclosed |
| US-5994312-A | Peptidyl compounds | DARWIN DISCOVERY, LTD. (GB) | 1999-11-30 | — | — | US | disclosed |
| WO-1999037667-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-5393875-A | Hypotensive, cardiotonic and antiischemic agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0509354-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | ACE 2233/4885ITGB3 4873/4885ITGA2B 4831/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | ACE 1944/4885ITGB3 2864/4885ITGA2B 3805/4885 |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | ACE 2383/4885ITGB3 4634/4885ITGA2B 4699/4885 |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ACE, EIF2AK2 | ACE 2/4885ITGB3 4399/4885ITGA2B 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.